Warfarin-Associated Bleeding and Thromboembolic Events in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.
| Title: | Warfarin-Associated Bleeding and Thromboembolic Events in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. |
|---|---|
| Authors: | Demsie DG; Department of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.; Addisu ZD; Department of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.; Tafere C; Department of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.; Bahiru B; Department of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.; Yismaw MB; Department of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.; Mihret G; St. Peter Hospital, Addis Ababa, Ethiopia.; Berhe DF; Department of Pharmacology, Biomedical Division, and Center for Equity in Global Surgery, University of Global Health Equity, Kigali, Rwanda. |
| Source: | Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2025 Oct; Vol. 34 (10), pp. e70225. |
| Publication Type: | Journal Article; Meta-Analysis; Systematic Review |
| Language: | English |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 9208369 Publication Model: Print Cited Medium: Internet ISSN: 1099-1557 (Electronic) Linking ISSN: 10538569 NLM ISO Abbreviation: Pharmacoepidemiol Drug Saf Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Chichester, West Sussex : Wiley, 1992- |
| MeSH Terms: | Anticoagulants*/adverse effects ; Anticoagulants*/administration & dosage ; Hemorrhage*/chemically induced ; Hemorrhage*/epidemiology ; Thromboembolism*/epidemiology ; Thromboembolism*/chemically induced ; Warfarin*/adverse effects ; Warfarin*/administration & dosage; Africa South of the Sahara/epidemiology ; Humans ; Observational Studies as Topic ; Prevalence |
| Abstract: | Background: Warfarin use in Sub-Saharan Africa is associated with elevated risks of thromboembolic events and bleeding, but precise prevalence estimates are lacking. This systematic review and meta-analysis aimed to quantify the prevalence of bleeding and thromboembolic events among patients on warfarin in Sub-Saharan Africa.; Methods: Comprehensive searches were conducted in MEDLINE via Ovid, PubMed, Embase via Ovid, Scopus, and Google Scholar to identify relevant studies. Primary outcomes included major and minor bleeding events, while thromboembolic events were secondary outcomes. Meta-analysis was conducted using RStudio version 4.3.3 with the meta and metaprop packages. Proportions were transformed using the Freeman-Tukey double arcsine method, and meta-regression was performed with the metafor package's escal, rma, and res functions. Publication bias was assessed via funnel plots and Egger's test, with a p value |
| References: | H. Hayssen, R. Cires‐Drouet, B. Englum, et al., “Systematic Review of Venous Thromboembolism Risk Categories Derived From Caprini Score,” Journal of Vascular Surgery. Venous and Lymphatic Disorders 10, no. 6 (2022): 1401–1409.e7, https://doi.org/10.1016/j.jvsv.2022.05.003.; A. Jacobs, F. Bassa, and E. H. Decloedt, “A Preliminary Review of Warfarin Toxicity in a Tertiary Hospital in Cape Town, South Africa,” Cardiovascular Journal of Africa 28, no. 6 (2017): 346–349, https://doi.org/10.5830/CVJA‐2017‐029.; S. Jame and G. Barnes, “Stroke and Thromboembolism Prevention in Atrial Fibrillation,” Heart & Brain: The Journal of the Heart and Brain Society 106, no. 1 (2020): 10–17, https://doi.org/10.1136/heartjnl‐2019‐314%E2%80%898.; P. L. Lutsey and N. A. Zakai, “Epidemiology and Prevention of Venous Thromboembolism,” Nature Reviews. Cardiology 20, no. 4 (2023): 248–262, https://doi.org/10.1038/s41569‐022‐00787‐6.; N. Masresha, E. A. Muche, A. Atnafu, and O. Abdela, “Evaluation of Warfarin Anticoagulation at University of Gondar Comprehensive Specialized Hospital, North‐West Ethiopia,” Journal of Blood Medicine 12 (2021): 189–195, https://doi.org/10.2147/JBM.S282948.; T. L. Ortel, I. Neumann, W. Ageno, et al., “American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism,” Blood Advances 4, no. 19 (2020): 4693–4738, https://doi.org/10.1182/bloodadvances.2020001830.; O. S. Anakwue and A. Madu, “Utilization of Oral Anticoagulation in a Teaching Hospital in Nigeria,” Annals of Medical and Health Sciences Research 4, no. Suppl 3 (2014): S286–S290, https://doi.org/10.4103/2141‐9248.141973.; E. Botsile and J. C. Mwita, “Incidence and Risk Factors for Thromboembolism and Major Bleeding in Patients With Mechanical Heart Valves: A Tertiary Hospital‐Based Study in Botswana,” Cardiovascular Journal of Africa 31, no. 4 (2020): 185–189, https://doi.org/10.5830/CVJA‐2020‐006.; M. A. Lorenz and T. W. Linneman, “Comparing Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Extreme Obesity,” Journal of Pharmacy Practice 36, no. 6 (2023): 1375–1382, https://doi.org/10.1177/08971900221116809.; A. E. Mihm, A. Bacchus, K. J. Harb, R. A. Menear, and S. A. Nisly, “Direct Oral Anticoagulants Versus Warfarin for the Treatment of Inferior Vena Cava Thrombus,” European Journal of Haematology 111, no. 6 (2023): 909–913, https://doi.org/10.1111/ejh.14097.; S. Ouali, A. Ben Halima, S. Chabrak, et al., “Epidemiological Characteristics, Management, and Outcomes of Atrial Fibrillation in Tunisia: Results From the National Tunisian Registry of Atrial Fibrillation (NATURE‐AF),” Clinical Cardiology 44, no. 4 (2021): 501–510, https://doi.org/10.1002/clc.23558.; R. G. Hart, L. A. Pearce, and M. I. Aguilar, “Meta‐Analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation,” Annals of Internal Medicine 146, no. 12 (2007): 857–867, https://doi.org/10.7326/0003‐4819‐146‐12‐200%E2%80%89706%E2%80%89190‐00007.; S. Yaghi, I. J. Saldanha, C. Misquith, et al., “Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta‐Analysis,” Stroke 53, no. 10 (2022): 3014–3024, https://doi.org/10.1161/STROKEAHA.122.039579.; A. T. Cohen, J. Sah, A. D. Dhamane, et al., “Effectiveness and Safety of Apixaban Versus Warfarin in Venous Thromboembolism Patients With Chronic Kidney Disease,” Thrombosis and Haemostasis 122, no. 6 (2022): 926–938, https://doi.org/10.1055/s‐0041‐1%E2%80%89740%E2%80%89254.; M. I. Ellenbogen, S. Ardeshirrouhanifard, J. B. Segal, M. B. Streiff, S. B. Deitelzweig, and D. J. Brotman, “Safety and Effectiveness of Apixaban Versus Warfarin for Acute Venous Thromboembolism in Patients With End‐Stage Kidney Disease: A National Cohort Study,” Journal of Hospital Medicine 17, no. 10 (2022): 809–818, https://doi.org/10.1002/jhm.12926.; K. Srivastava, N. Patel, M. Tabbara, et al., “Thromboembolism, Bleeding, and Mortality Incidence of Direct Oral Anticoagulants Versus Warfarin Postbariatric Surgery,” American Journal of Medicine 134, no. 11 (2021): 1403–1412.e2, https://doi.org/10.1016/j.amjmed.2021.06.021.; S. Kohsaka, J. Katada, K. Saito, et al., “Safety and Effectiveness of Non‐Vitamin K Oral Anticoagulants Versus Warfarin in Real‐World Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Analysis of Contemporary Japanese Administrative Claims Data,” Open Heart 7, no. 1 (2020): e001232, https://doi.org/10.1136/openhrt‐2019‐001232.; N. O. Ahmed, B. Osman, Y. M. Abdelhai, and T. M. H. El‐Hadiyah, “Impact of Clinical Pharmacist Intervention in Anticoagulation Clinic in Sudan,” International Journal of Clinical Pharmacy 39, no. 4 (2017): 769–773, https://doi.org/10.1007/s11096‐017‐0475‐x.; T. G. Fenta, T. Assefa, and B. Alemayehu, “Quality of Anticoagulation Management With Warfarin Among Outpatients in a Tertiary Hospital in Addis Ababa, Ethiopia: A Retrospective Cross‐Sectional Study,” BMC Health Services Research 17, no. 1 (2017): 389, https://doi.org/10.1186/s12913‐017‐2330‐0.; L. J. Jonkman, M. P. Gwanyanya, M. N. Kakololo, R. Verbeeck, and B. S. Singu, “Assessment of Anticoagulation Management in Outpatients Attending a Warfarin Clinic in Windhoek, Namibia,” Drugs & Therapy Perspectives 35 (2019): 341–346, https://www.semanticscholar.org/paper/Assessment‐of‐anticoagulation‐management‐in‐a‐in‐Jonkman‐Gwanyanya/d81cb5fc164b200efb988db1808d013a5caa0378.; B. O. Sonuga, D. A. Hellenberg, C. S. Cupido, and C. Jaeger, “Profile and Anticoagulation Outcomes of Patients on Warfarin Therapy in an Urban Hospital in Cape Town, South Africa,” African Journal of Primary Health & Family Medicine 8, no. 1 (2016): e1–e8, https://doi.org/10.4102/phcfm.v8i1.1032.; G. A. Wells, B. Shea, D. O'Connell, et al., “The Newcastle‐Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta‐Analyses,” 2000.; S. Schulman and C. Kearon, “Definition of Major Bleeding in Clinical Investigations of Antihemostatic Medicinal Products in Non‐Surgical Patients,” Journal of Thrombosis and Haemostasis 3, no. 4 (2005): 692–694, https://doi.org/10.1111/j.1538‐7836.2005.01204.x.; R. Getachew, T. A. Tadesse, B. A. Shashu, A. Degu, and G. Alemkere, “Anticoagulation Management in Patients Receiving Warfarin at Private Cardiac Centers in Addis Ababa, Ethiopia,” Journal of Blood Medicine 14 (2023): 107–117, https://doi.org/10.2147/JBM.S397189.; R. C. Anakwue, S. Ocheni, and A. J. Madu, “Utilization of Oral Anticoagulation in a Teaching Hospital in Nigeria,” Annals of Medical and Health Sciences Research 4, no. 3 (2014): 286–290.; N. S. Yimer, A. A. Abiye, S. U. Hussen, and T. A. Tadesse, “Anticoagulation Control, Outcomes, and Associated Factors in Patients With Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia,” Clinical and Applied Thrombosis/Hemostasis 27 (2021): 10760296211049786, https://doi.org/10.1177/10760296211049786.; Z. Liyew, A. Tadesse, N. Bekele, and T. Tsegaye, “Evaluation of Anticoagulation Control Among Patients Taking Warfarin in University of Gondar Hospital, Northwest Ethiopia,” Advances in Hematology 2021 (2021): 1–8, https://doi.org/10.1155/2021/7530997.; A. Salaheldin, “Using WhatsApp Smartphone Application to Monitor INR in Patients on Warfarin: First Experience With 21 Patients,” Sudan Heart Journal 7, no. 1 (2019): 1–8.; A. Jacobs, F. Bassa, and E. H. Decloedt, “A Preliminary Review of Warfarin Toxicity in a Tertiary Hospital in Cape Town, South Africa,” Cardiovascular Journal of Africa 28, no. 6 (2017): 346–349.; K. Hosokawa, K. Abe, K. Funakoshi, et al., “Long‐Term Outcome of Chronic Thromboembolic Pulmonary Hypertension Using Direct Oral Anticoagulants and Warfarin: A Japanese Prospective Cohort Study,” Journal of Thrombosis and Haemostasis 21, no. 8 (2023): 2151–2162, https://doi.org/10.1016/j.jtha.2023.03.036.; Y. Dogan, A. Az, O. Sogut, T. Akdemir, and O. Kaplan, “Bleeding Events in the Emergency Department With Warfarin Versus Novel Oral Anticoagulants: A Five‐Year Analysis,” Nigerian Journal of Clinical Practice 25, no. 8 (2022): 1308–1317, https://doi.org/10.4103/njcp.njcp_125_22.; J. M. Ferro, J. M. Coutinho, F. Dentali, et al., “Safety and Efficacy of Dabigatran Etexilate vs. Dose‐Adjusted Warfarin in Patients With Cerebral Venous Thrombosis,” JAMA Neurology 76, no. 12 (2019): 1457–1465, https://doi.org/10.1001/jamaneurol.2019.2764.; R. Cardoso, C. M. P. Ternes, G. B. Justino, et al., “Non‐Vitamin K Antagonists Versus Warfarin in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review and Meta‐Analysis,” American Journal of Medicine 135, no. 2 (2022): 228–234.e1, https://doi.org/10.1016/j.amjmed.2021.08.026.; A. M. Holbrook, J. A. Pereira, R. Labiris, et al., “Systematic Overview of Warfarin and Its Drug and Food Interactions,” Archives of Internal Medicine 165, no. 10 (2005): 1095–1106, https://doi.org/10.1001/archinte.165.10.1095.; A. Willeford, W. Zhu, C. Stevens, and I. C. Thomas, “Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus,” Annals of Pharmacotherapy 55, no. 7 (2021): 839–845, https://doi.org/10.1177/1060028020975111.; C. M. Jackson, M. P. Esnouf, and T. L. Lindahl, “A Critical Evaluation of the Prothrombin Time for Monitoring Oral Anticoagulant Therapy,” Pathophysiology of Haemostasis and Thrombosis 33, no. 1 (2003): 43–51, https://doi.org/10.1159/000071641.; S. D. Pokorney, D. N. Holmes, L. Thomas, et al., “Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation,” JAMA Cardiology 4, no. 8 (2019): 756–764, https://doi.org/10.1001/jamacardio.2019.1960.; T. A. Tadesse, G. T. Tegegne, D. Yadeta, L. Chelkaba, and T. G. Fenta, “Anticoagulation Control, Outcomes, and Associated Factors in Long‐Term‐Care Patients Receiving Warfarin in Africa: A Systematic Review,” Thrombosis Journal 20, no. 1 (2022): 58, https://doi.org/10.1186/s12959‐022‐00416‐9.; I. G. Asiimwe, C. Waitt, C. Sekaggya‐Wiltshire, et al., “Developing and Validating a Clinical Warfarin Dose‐Initiation Model for Black‐African Patients in South Africa and Uganda,” Clinical Pharmacology and Therapeutics 109, no. 6 (2021): 1564–1574, https://doi.org/10.1002/cpt.2128.; D. K. Kumar, C. R. S. Uppugunduri, D. G. Shewade, S. C. B.v, and C. Adithan, “Influence of CYP2C9 Polymorphisms on Plasma Concentration of Warfarin and 7‐Hydroxy Warfarin in South Indian Patients,” Current Drug Metabolism 22, no. 12 (2022): 989–995.; S. Muyambo, A. Ndadza, N. D. Soko, et al., “Warfarin Pharmacogenomics for Precision Medicine in Real‐Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes,” Omics: A Journal of Integrative Biology 26, no. 1 (2022): 35–50, https://doi.org/10.1089/omi.2021.0199.; J. P. Mouton, M. Blockman, C. Sekaggya‐Wiltshire, et al., “Improving Anticoagulation in Sub‐Saharan Africa: What Are the Challenges and How Can We Overcome Them?,” British Journal of Clinical Pharmacology 87, no. 8 (2021): 3056–3068, https://doi.org/10.1111/bcp.14768.; W. Yang, J. Ma, W. Hu, H. Dai, and H. Xu, “Associated Factors and Safety of the Rapidly Achieving First Therapeutic Target of Warfarin in Hospitalized Patients: A Retrospective Cohort Study,” International Journal of Clinical Pharmacy 44, no. 4 (2022): 939–946, https://doi.org/10.1007/s11096‐022‐01404‐9.; P. Parbhoo and B. Jacobson, “A Comparison Between TTR and FIR as a Measure of the Quality of Anticoagulation in Patients With Atrial Fibrillation,” Wits Journal of Clinical Medicine 1 (2019): 23–30, https://doi.org/10.18772/26180197.2019.v1n1a4.; B. S. Stambler and L. M. Ngunga, “Atrial Fibrillation in Sub‐Saharan Africa: Epidemiology, Unmet Needs, and Treatment Options,” International Journal of General Medicine 8 (2015): 231–242, https://doi.org/10.2147/IJGM.S84537.; R. Anakwue, “Anticoagulation in Sub‐Saharan Africa With the Advent of Non‐Vitamin K Antagonist Oral Anticoagulants,” Nigerian Journal of Medicine 29 (2020): 187, https://doi.org/10.4103/NJM.NJM_12_20. |
| Contributed Indexing: | Keywords: Sub‐Saharan Africa; bleeding; thromboembolic event; warfarin |
| Substance Nomenclature: | 0 (Anticoagulants); 5Q7ZVV76EI (Warfarin) |
| Entry Date(s): | Date Created: 20250926 Date Completed: 20250926 Latest Revision: 20250926 |
| Update Code: | 20260130 |
| DOI: | 10.1002/pds.70225 |
| PMID: | 40999745 |
| Database: | MEDLINE |
Journal Article; Meta-Analysis; Systematic Review